JP2021513077A - 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー - Google Patents

認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー Download PDF

Info

Publication number
JP2021513077A
JP2021513077A JP2020542645A JP2020542645A JP2021513077A JP 2021513077 A JP2021513077 A JP 2021513077A JP 2020542645 A JP2020542645 A JP 2020542645A JP 2020542645 A JP2020542645 A JP 2020542645A JP 2021513077 A JP2021513077 A JP 2021513077A
Authority
JP
Japan
Prior art keywords
adm
dementia
antibody
adrenomedullin
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513077A5 (https=
JPWO2019154900A5 (https=
Inventor
メランデル オッレ
メランデル オッレ
Original Assignee
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング, シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2021513077A publication Critical patent/JP2021513077A/ja
Publication of JP2021513077A5 publication Critical patent/JP2021513077A5/ja
Publication of JPWO2019154900A5 publication Critical patent/JPWO2019154900A5/ja
Priority to JP2023174585A priority Critical patent/JP2024001208A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020542645A 2018-02-08 2019-02-07 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー Pending JP2021513077A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174585A JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18155682 2018-02-08
EP18155682.0 2018-02-08
PCT/EP2019/052982 WO2019154900A1 (en) 2018-02-08 2019-02-07 Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174585A Division JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Publications (3)

Publication Number Publication Date
JP2021513077A true JP2021513077A (ja) 2021-05-20
JP2021513077A5 JP2021513077A5 (https=) 2022-08-04
JPWO2019154900A5 JPWO2019154900A5 (https=) 2022-08-04

Family

ID=61188647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542645A Pending JP2021513077A (ja) 2018-02-08 2019-02-07 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Country Status (12)

Country Link
US (2) US20210302440A1 (https=)
EP (1) EP3749959A1 (https=)
JP (2) JP2021513077A (https=)
KR (1) KR102717599B1 (https=)
CN (2) CN111902721B (https=)
AU (1) AU2019219071A1 (https=)
BR (1) BR112020014940A2 (https=)
CA (1) CA3090736A1 (https=)
IL (1) IL276564A (https=)
MX (1) MX421834B (https=)
SG (1) SG11202006686SA (https=)
WO (1) WO2019154900A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220146538A (ko) 2020-02-26 2022-11-01 페아엠 테라그노스틱스 게엠베하 치료 목적을 위한 펩티딜글리신 알파-아미드화 모노옥시게나제 (pam)의 용도
CN115280148A (zh) 2020-02-26 2022-11-01 Pam治疗诊断有限公司 测定肽酰甘氨酸α-酰胺化单加氧酶(PAM)的方法及其用于诊断目的的用途
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CN120731367A (zh) 2023-03-17 2025-09-30 Pam治疗诊断有限公司 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途
WO2025133203A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009503524A (ja) * 2005-08-01 2009-01-29 ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト 神経変性疾患の診断のためのｉｎｖｉｔｒｏ方法
JP2009540309A (ja) * 2006-06-16 2009-11-19 ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト 神経変性障害の診断および早期診断のためのｉｎｖｉｔｒｏマルチパラメータ測定法
JP2011511282A (ja) * 2008-02-01 2011-04-07 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療の必要な軽度認知障害患者の特定方法とかかる患者の治療
US20130315912A1 (en) * 2010-08-30 2013-11-28 Centre National De La Recherche Scientifique Antibodies that Bind to Adrenomedullin and to Adrenomedullin Receptors and the Uses Thereof as Drugs
JP2014533827A (ja) * 2011-11-16 2014-12-15 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法
JP2014533671A (ja) * 2011-11-16 2014-12-15 アドレノメト アクチェンゲゼルシャフト 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
CA2620738C (en) 2005-08-31 2010-10-12 Ezaki Glico Co., Ltd. Tablet for removing tongue coating
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
US20160230227A1 (en) * 2012-12-21 2016-08-11 The New York Stem Cell Foundation Methods of treating alzheimer's disease
EP4231018A3 (en) * 2016-07-08 2023-11-15 SphingoTec GmbH Adrenomedullin for assessing congestion in a subject with acute heart failure

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009503524A (ja) * 2005-08-01 2009-01-29 ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト 神経変性疾患の診断のためのｉｎｖｉｔｒｏ方法
JP2009540309A (ja) * 2006-06-16 2009-11-19 ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト 神経変性障害の診断および早期診断のためのｉｎｖｉｔｒｏマルチパラメータ測定法
JP2011511282A (ja) * 2008-02-01 2011-04-07 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療の必要な軽度認知障害患者の特定方法とかかる患者の治療
US20130315912A1 (en) * 2010-08-30 2013-11-28 Centre National De La Recherche Scientifique Antibodies that Bind to Adrenomedullin and to Adrenomedullin Receptors and the Uses Thereof as Drugs
JP2014533827A (ja) * 2011-11-16 2014-12-15 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法
JP2014533671A (ja) * 2011-11-16 2014-12-15 アドレノメト アクチェンゲゼルシャフト 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOLM, H. ET AL.: "Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based pr", JOURNAL OF INTERNATIONAL MEDICINE, vol. 282, JPN6022054590, 2017, pages 94 - 101, ISSN: 0004959634 *
ICHIKI, Y. ET AL.: "Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma", FEBS LETTERS, vol. 338, JPN6022054591, 1994, pages 6 - 10, ISSN: 0004959633 *

Also Published As

Publication number Publication date
CN111902721B (zh) 2024-12-13
JP2024001208A (ja) 2024-01-09
US20230221339A1 (en) 2023-07-13
CA3090736A1 (en) 2019-08-15
KR102717599B1 (ko) 2024-10-14
SG11202006686SA (en) 2020-08-28
CN119770645A (zh) 2025-04-08
US20210302440A1 (en) 2021-09-30
MX2020008345A (es) 2020-09-25
BR112020014940A2 (pt) 2020-12-08
MX421834B (es) 2025-03-14
RU2020129154A3 (https=) 2022-03-10
RU2020129154A (ru) 2022-03-10
KR20200135947A (ko) 2020-12-04
IL276564A (en) 2020-09-30
EP3749959A1 (en) 2020-12-16
WO2019154900A1 (en) 2019-08-15
AU2019219071A1 (en) 2020-07-30
CN111902721A (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
US20230221339A1 (en) Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-andrenomedullin binder for use in therapy or prevention of dementia
JP7654597B2 (ja) 急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン
JP6336911B2 (ja) アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法
KR20200130354A (ko) 신경퇴행을 검출하기 위한 분석
US20220268761A1 (en) Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
JP2025530718A (ja) 抗タウｍｔｂｒ抗体、ならびにタウの切断された断片の検出方法およびその用途
JPWO2011045945A1 (ja) アミロイドβのターン構造を認識する抗体
JP2026035582A (ja) ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３
US20230357383A1 (en) Anti-ADM-antibodies binding to the free N-terminus for accelerated transition of ADM-Gly to bio-ADM in patients with ADM-Gly/ bio-ADM ratio above a threshold and combination with vitamin C
US20220260593A1 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
RU2811309C2 (ru) Адреномедуллин (adm) для диагностики и/или прогнозирования деменции и антиадреномедуллин-связующий агент для применения в терапии или профилактике деменции
HK40121614A (zh) 用於诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
HK40034157A (en) Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
RU2835424C2 (ru) Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
RU2776811C2 (ru) Мониторинг терапии при лечении связывающим веществом против адреномедуллина (adm)
EA049359B1 (ru) Анализ проб, полученных из крови, для обнаружения таупатии или амилоидогенного заболевания
HK40096066A (zh) 用於检测tau蛋白病或淀粉样蛋白形成性疾病的基於血液的测定
CN119604526A (zh) 用于治疗或预防休克的抗肾上腺髓质素（ADM）抗体或抗ADM抗体片段或抗ADM非Ig支架
HK40031761A (en) Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
HK40005377B (zh) 肾上腺髓质素用於评估急性心力衰竭患者的充血
HK1202624B (en) Adrenomedullin assays and methods for determining mature adrenomedullin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231031

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231201